Understanding how certain immune cells contribute to heart inflammation caused by cancer treatments.
Official title: CXCL9/10 Macrophage Induced CXCR3+ T-cell Recruitment to the Heart Contributes to Immunotherapy Myocarditis
Funded at Stanford University · NIH-10867164 · Data updated 2026-11-12
This study is looking at how certain immune cells can cause heart inflammation in people receiving cancer treatment, with the goal of finding ways to keep patients safer during their therapy.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $117,804 |
| NIH project number | 1R03HL173146-01 |
| Project ID | NIH-10867164 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing immunotherapy for advanced cancer who may be at risk for myocarditis.
✕Less likely to help
Patients not receiving immunotherapy or those without a history of heart issues may not benefit from this research.
What this research studies
This research investigates the role of specific immune cells, particularly macrophages and T-cells, in causing heart inflammation known as myocarditis, which can occur as a side effect of cancer immunotherapy. By using advanced mouse models and high-throughput techniques, the study aims to understand how these immune cells interact and contribute to heart damage. The findings could lead to better management strategies for patients experiencing this serious side effect, ultimately improving their safety during cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments that minimize heart inflammation in patients receiving immunotherapy for cancer.
How similar studies have gone: Previous research has shown that understanding immune cell interactions can lead to significant advancements in managing side effects of cancer treatments, indicating potential for success in this area.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Zhu, Han — Stanford University
- Study coordinator: Zhu, Han
Related research
Other NIH-funded projects on the same topics.
-
Targeted CXCR3 blockade to treat immunotherapy-related heart inflammation
A targeted drug approach aims to prevent or lessen heart inflammation caused by immune therapies in cancer patients, using CXCR3-blocking strategies.
-
Understanding why immunotherapy can affect the heart and how to protect it
Researchers are studying why certain cancer immunotherapies cause dangerous heart inflammation and how to prevent it, with a focus on patients who receive immune-boosting treatments.
-
Why some cancer immunotherapy drugs cause dangerous heart inflammation
Seeing if blocking a chemical signal that draws T cells into the heart can prevent dangerous heart inflammation in people receiving immune checkpoint inhibitor cancer drugs.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.